Loading the map…
Research and experimental development on biotechnology · London
Lift Therapeutics
Lift Therapeutics Limited
Private limited company registered in London, classed under “Research and experimental development on biotechnology”.
Headline figures
FY to Dec 2025 · Company only
Turnover
For subscribers
Profit after tax
−£1.31m
Net assets
For subscribers
Cash
For subscribers
Employees
For subscribers
Retained reserves
For subscribers
What the numbers say
4 findings from the figures, in plain English
Written by rules from the figures on this page. Not a forecast or a credit opinion.
History
| £ | 2021 | 2022 | 2023 | 2024* | 2025 |
|---|---|---|---|---|---|
| Profit after tax | −£1.31m | ||||
| Turnover | |||||
| Net assets | |||||
| Cash | |||||
| Employees | |||||
| Retained reserves |
Every figure for all 5 years
“—” means we did not find the figure in a source; it is never filled with an estimate. * Restated: the next year's accounts printed different figures for this year, and those later figures are shown.
Balance sheet and ratios
From the filed balance sheets · £
| Balance sheet | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed assets | ||||
| Current assets | ||||
| of which debtors | ||||
| of which cash | ||||
| Creditors due within a year | ||||
| Net current assets | ||||
| Net assets | ||||
| Ratios | ||||
| Return on equityProfit after tax as a share of net assets | ||||
| Current ratioCurrent assets for every £1 owed within a year | ||||
| Cash ratioCash for every £1 owed within a year | ||||
| Creditors to assetsEverything owed to creditors as a share of fixed plus current assets | ||||
7 balance-sheet lines and 4 ratios, every year
A ratio appears only for years where every line it needs was filed. Lines are as tagged in the accounts; nothing is added up or estimated.
Questions people ask
›What does Lift Therapeutics do?
Private limited company registered in London, classed under “Research and experimental development on biotechnology”. In its own words: “Lift Therapeutics’ Immuno-modulatory Alpha Neutrophils (IMANs) are first-in-class, off-the-shelf neutrophil-lineage cell therapies designed to directly kill tumor cells and re-ignite anti-tumor immunity in cancer patients who progress. Our upcoming first-in-human Phase 1 clinical study will assess IMANs’ safety, biodistribution, and anti-tumor activity in patients with advanced cervical, head, and neck cancers.”
›How much turnover does Lift Therapeutics make?
Answered in the full report
›Is Lift Therapeutics profitable?
No: it made a loss after tax of £1.31m in the year to 31 December 2025, its latest filed accounts.
›How many people work at Lift Therapeutics?
Answered in the full report
›Where is Lift Therapeutics based?
Its registered office is London Bioscience Innovation Centre, 2 Royal College Street, London, NW1 0NH, in London.
›When was Lift Therapeutics founded?
Lift Therapeutics Limited was incorporated on 23 October 2014.
›Is Lift Therapeutics still trading?
The register lists Lift Therapeutics Limited as active.
